Assembly Biosciences Presents Positive Interim Data from Phase 1a and 1b Studies of ABI-H0731 in HBV Patients in a Late-Breaker Session at the EASL Conference

    NEXT STORY
    Helsinn Provides Grant for ESMO’s Preceptorship Programme for Supportive and Palliative Care
    PREV STORY
    GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Alberta Medical Association honours Albertans for their extraordinary contributions to health care

    CALGARY, Alberta, Sept. 20, 2018 (GLOBE NEWSWIRE) -- On Friday, September 21, the Alberta ...

    author_avatar
    NASDAQ Market News

    Surgical Care Affiliates, Inc. to Present at 34th Annual J.P. Morgan Healthcare Conference

    DEERFIELD, Ill., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Surgical Care Affiliates, Inc. (NASDAQ:SCAI) (“SCA”) ...

    author_avatar
    NASDAQ Market News

    Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma

    author_avatar
    NASDAQ Market News